- Home
- NIU vs IFRX Comparison
NIU vs IFRX Comparison
Compare NIU & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIU
- IFRX
- Stock Information
- Founded
- NIU 2014
- IFRX 2007
- Country
- NIU China
- IFRX Germany
- Employees
- NIU N/A
- IFRX N/A
- Industry
- NIU Auto Manufacturing
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- NIU Consumer Discretionary
- IFRX Health Care
- Exchange
- NIU Nasdaq
- IFRX Nasdaq
- Market Cap
- NIU 182.4M
- IFRX 117.8M
- IPO Year
- NIU 2018
- IFRX 2017
- Fundamental
- Price
- NIU $2.56
- IFRX $1.17
- Analyst Decision
- NIU
- IFRX Strong Buy
- Analyst Count
- NIU 0
- IFRX 1
- Target Price
- NIU N/A
- IFRX $8.00
- AVG Volume (30 Days)
- NIU 904.1K
- IFRX 628.1K
- Earning Date
- NIU 03-17-2025
- IFRX 05-07-2025
- Dividend Yield
- NIU N/A
- IFRX N/A
- EPS Growth
- NIU N/A
- IFRX N/A
- EPS
- NIU N/A
- IFRX N/A
- Revenue
- NIU $420,244,416.00
- IFRX $187,930.00
- Revenue This Year
- NIU $16.60
- IFRX $396.02
- Revenue Next Year
- NIU $24.42
- IFRX $155.22
- P/E Ratio
- NIU N/A
- IFRX N/A
- Revenue Growth
- NIU 5.83
- IFRX 177.12
- 52 Week Low
- NIU $1.60
- IFRX $1.15
- 52 Week High
- NIU $3.50
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- NIU 57.01
- IFRX 26.15
- Support Level
- NIU $2.26
- IFRX $1.76
- Resistance Level
- NIU $2.55
- IFRX $1.34
- Average True Range (ATR)
- NIU 0.21
- IFRX 0.13
- MACD
- NIU -0.01
- IFRX -0.00
- Stochastic Oscillator
- NIU 49.21
- IFRX 9.15
About NIU Niu Technologies
Niu Technologies designs, manufactures and sells high-performance electric motorcycles, scooters, bicycles, and kick-scooters. The company has a product portfolio consisting of electric motorcycle, moped and bicycle series, including the NQi, MQi, UQi, F series, and others, and micro-mobility series, including the kick-scooter series KQi and the e-bike series BQi. The company's principal operations and geographic markets are predominantly in the People's Republic of China. It also generates revenue from Europe and other regions.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.